S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

$9.46
-0.21 (-2.17%)
(As of 02/28/2024 ET)
Today's Range
$9.42
$9.75
50-Day Range
$6.05
$9.74
52-Week Range
$2.82
$10.13
Volume
3.99 million shs
Average Volume
6.70 million shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.36

Ardelyx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
30.6% Upside
$12.36 Price Target
Short Interest
Bearish
12.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.25mentions of Ardelyx in the last 14 days
Based on 44 Articles This Week
Insider Trading
Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to $0.15 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

99th out of 958 stocks

Pharmaceutical Preparations Industry

30th out of 419 stocks


ARDX stock logo

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

ARDX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Stocks on the Launchpad: The Next 3 Market Sensations
Ardelyx (NASDAQ:ARDX) Downgraded by StockNews.com
Ardelyx (NASDAQ:ARDX) Stock Price Up 6% on Analyst Upgrade
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 Ardelyx Inc Earnings Call
Ardelyx (NASDAQ:ARDX) Stock Rating Reaffirmed by Wedbush
Ardelyx (NASDAQ:ARDX) PT Raised to $15.00 at Piper Sandler
Ardelyx (NASDAQ:ARDX) Shares Gap Down on Disappointing Earnings
Where Ardelyx Stands With Analysts
Ardelyx: Q4 Earnings Snapshot
Ardelyx (ARDX) Scheduled to Post Quarterly Earnings on Thursday
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARDX
Employees
133
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$12.36
High Stock Price Target
$15.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+30.6%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-66,070,000.00
Pretax Margin
-52.65%

Debt

Sales & Book Value

Annual Sales
$124.46 million
Book Value
$0.72 per share

Miscellaneous

Free Float
219,888,000
Market Cap
$2.20 billion
Optionable
Optionable
Beta
0.92

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price target for 2024?

7 analysts have issued twelve-month price objectives for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's share price to reach $12.36 in the next year. This suggests a possible upside of 30.6% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 at the beginning of 2024. Since then, ARDX stock has increased by 52.6% and is now trading at $9.46.
View the best growth stocks for 2024 here
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 30,060,000 shares, an increase of 6.7% from the January 31st total of 28,160,000 shares. Based on an average trading volume of 6,360,000 shares, the days-to-cover ratio is presently 4.7 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $34.36 million during the quarter, compared to the consensus estimate of $34.26 million. Ardelyx had a negative net margin of 53.08% and a negative trailing twelve-month return on equity of 43.57%. The company's revenue was down 22.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.06 earnings per share.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.61%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%), Price T Rowe Associates Inc. MD (1.00%) and Northern Trust Corp (0.94%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 2/29/2024 by MarketBeat.com Staff